165 related articles for article (PubMed ID: 37569478)
1. NMR-Chemical-Shift-Driven Protocol Reveals the Cofactor-Bound, Complete Structure of Dynamic Intermediates of the Catalytic Cycle of Oncogenic KRAS G12C Protein and the Significance of the Mg
Gadanecz M; Fazekas Z; Pálfy G; Karancsiné Menyhárd D; Perczel A
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569478
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophoric analogs of sotorasib-entrapped KRAS G12C in its inactive GDP-bound conformation: covalent docking and molecular dynamics investigations.
Oyedele AK; Ogunlana AT; Boyenle ID; Ibrahim NO; Gbadebo IO; Owolabi NA; Ayoola AM; Francis AC; Eyinade OH; Adelusi TI
Mol Divers; 2023 Aug; 27(4):1795-1807. PubMed ID: 36271195
[TBL] [Abstract][Full Text] [Related]
3.
Pálfy G; Vida I; Perczel A
Biomol NMR Assign; 2020 Apr; 14(1):1-7. PubMed ID: 31468366
[TBL] [Abstract][Full Text] [Related]
4. NMR
Sharma AK; Dyba M; Tonelli M; Smith B; Gillette WK; Esposito D; Nissley DV; McCormick F; Maciag AE
Biomol NMR Assign; 2022 Apr; 16(1):1-8. PubMed ID: 34686998
[TBL] [Abstract][Full Text] [Related]
5. KRAS is vulnerable to reversible switch-II pocket engagement in cells.
Vasta JD; Peacock DM; Zheng Q; Walker JA; Zhang Z; Zimprich CA; Thomas MR; Beck MT; Binkowski BF; Corona CR; Robers MB; Shokat KM
Nat Chem Biol; 2022 Jun; 18(6):596-604. PubMed ID: 35314814
[TBL] [Abstract][Full Text] [Related]
6. More to the RAS Story: KRAS
Lietman CD; Johnson ML; McCormick F; Lindsay CR
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
[TBL] [Abstract][Full Text] [Related]
7. Probing the KRas Switch II Groove by Fluorine NMR Spectroscopy.
Peacock DM; Kelly MJS; Shokat KM
ACS Chem Biol; 2022 Oct; 17(10):2710-2715. PubMed ID: 36166818
[TBL] [Abstract][Full Text] [Related]
8. NMR
Sharma AK; Lee SJ; Rigby AC; Townson SA
Biomol NMR Assign; 2018 Oct; 12(2):269-272. PubMed ID: 29721757
[TBL] [Abstract][Full Text] [Related]
9. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
[TBL] [Abstract][Full Text] [Related]
10.
Tu G; Liu Q; Qiu Y; Leung EL; Yao X
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430323
[TBL] [Abstract][Full Text] [Related]
11. Modeling receptor flexibility in the structure-based design of KRAS
Zhu K; Li C; Wu KY; Mohr C; Li X; Lanman B
J Comput Aided Mol Des; 2022 Aug; 36(8):591-604. PubMed ID: 35930206
[TBL] [Abstract][Full Text] [Related]
12. KRAS
Lou K; Steri V; Ge AY; Hwang YC; Yogodzinski CH; Shkedi AR; Choi ALM; Mitchell DC; Swaney DL; Hann B; Gordan JD; Shokat KM; Gilbert LA
Sci Signal; 2019 May; 12(583):. PubMed ID: 31138768
[TBL] [Abstract][Full Text] [Related]
13. NMR
Sharma AK; Lee SJ; Zhou M; Rigby AC; Townson SA
Biomol NMR Assign; 2019 Apr; 13(1):227-231. PubMed ID: 30798456
[TBL] [Abstract][Full Text] [Related]
14. D-1553: A novel KRAS
Shi Z; Weng J; Niu H; Yang H; Liu R; Weng Y; Zhu Q; Zhang Y; Tao L; Wang Z; Huh SJ; Jiang Y; Mei H; Dai X; Zhang L; Wang Y
Cancer Sci; 2023 Jul; 114(7):2951-2960. PubMed ID: 37158138
[TBL] [Abstract][Full Text] [Related]
15. Impacts of Mutations in the P-Loop on Conformational Alterations of KRAS Investigated with Gaussian Accelerated Molecular Dynamics Simulations.
Shi S; Zheng L; Ren Y; Wang Z
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049650
[TBL] [Abstract][Full Text] [Related]
16. Real-time monitoring of the reaction of KRAS G12C mutant specific covalent inhibitor by in vitro and in-cell NMR spectroscopy.
Zhao Q; Haga R; Tamura S; Shimada I; Nishida N
Sci Rep; 2023 Nov; 13(1):19253. PubMed ID: 37935773
[TBL] [Abstract][Full Text] [Related]
17. Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS
Bröker J; Waterson AG; Smethurst C; Kessler D; Böttcher J; Mayer M; Gmaschitz G; Phan J; Little A; Abbott JR; Sun Q; Gmachl M; Rudolph D; Arnhof H; Rumpel K; Savarese F; Gerstberger T; Mischerikow N; Treu M; Herdeis L; Wunberg T; Gollner A; Weinstabl H; Mantoulidis A; Krämer O; McConnell DB; W Fesik S
J Med Chem; 2022 Nov; 65(21):14614-14629. PubMed ID: 36300829
[TBL] [Abstract][Full Text] [Related]
18. Clinical Acquired Resistance to KRAS
Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
[TBL] [Abstract][Full Text] [Related]
19. Assessment of KRAS G12C Target Engagement by a Covalent Inhibitor in Tumor Biopsies Using an Ultra-Sensitive Immunoaffinity 2D-LC-MS/MS Approach.
Meng L; Chan EW; Ng C; Aimi J; Tran JC; Oh AJ; Merchant M; Purkey HE; Heffron TP; Kaur S; Xu K; Shi Z; He J
Anal Chem; 2022 Sep; 94(37):12927-12933. PubMed ID: 36083155
[No Abstract] [Full Text] [Related]
20. Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS
Mortier J; Friberg A; Badock V; Moosmayer D; Schroeder J; Steigemann P; Siegel F; Gradl S; Bauser M; Hillig RC; Briem H; Eis K; Bader B; Nguyen D; Christ CD
ChemMedChem; 2020 May; 15(10):827-832. PubMed ID: 32237114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]